Biotech Stocks At 52-Week Highs - RNXT +15%, EOLS, CRNX, APGE
RenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.
How this was made
The 30-second read
Why it matters
Multiple high‑impact events—positive trial data and two multi‑billion‑dollar acquisition announcements—provide fresh catalysts for the stocks involved.
Market read
The simultaneous occurrence of trial success and large M&A deals creates a notable bullish bias for the biotech sector.
What to watch
Regulatory approval risk for the acquisitions and potential competition from other biotech pipelines.
Background
The article lists biotech companies that reached 52‑week highs on August 31 2026 due to trial results, earnings, and announced acquisitions.
Ticker impact
RNXT reported positive Phase 3 trial data and its stock rose 15% to a 52‑week high.
upward momentum in the short term
Phase 3 data is material for biotech investors and the stock already jumped.
EOLS posted Q2 revenue growth of 21% and its shares hit a 52‑week high of $9.15.
moderate upside if guidance holds
Revenue beat and guidance raise expectations, but no new catalyst beyond the earnings release.
CRNX announced a definitive acquisition agreement by Vertex for $10 billion, sending the stock to a 52‑week high.
upward pressure until closing, then integration risk
A large‑scale M&A deal is a material event for shareholders.
APGE disclosed a definitive agreement to be acquired by AbbVie for approximately $10.9 billion, pushing the share price to a 52‑week high.
significant upside pending deal close
Another major acquisition with a double‑digit billion‑dollar valuation.
Market effects
Biotech sector may see broader rally as multiple peers announce major deals and trial data.
U.S. biotech stocks gain momentum, potentially lifting related ETFs.
Large M&A deals highlight continued consolidation in the global pharma industry.
Counterpoint
Deal premiums may be overvalued; integration risks could depress post‑close performance.
Key entities
- companyRenovoRx Inc.
Biotech firm reporting Phase 3 trial data.
- companyEvolus Inc.
Aesthetic injectables maker reporting Q2 results.
- companyCrinetics Pharmaceuticals Inc.
Biotech firm being acquired by Vertex.
- companyApogee Therapeutics Inc.
Biotech firm being acquired by AbbVie.
